Accessibility

Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

clonoseq logo

The First and Only FDA-cleared Assay for Measurable Residual Disease Detection

MRD detection in bone marrow from patients with multiple myeloma and B-cell acute lymphoblastic leukemia (ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL)

Doctor and patient

MRD: A powerful way to assess response and predict patient outcomes


Measurable (or minimal) residual disease (MRD) refers to the small number of cancer cells that may remain in a patient’s body during and after treatment. Clinical practice guidelines recognize that MRD status is a reliable indicator of clinical outcome and response to therapy in myeloma, ALL and CLL patients.1,2,3,4

The clonoSEQ® Assay is an MRD assessment tool powered by next-generation sequencing (NGS) technology and differentiated from other NGS assays by groundbreaking advances in chemistry and proprietary bioinformatics.5,6

Graphic: List of reasons to use
Graphic: Why Choose
Graphic: How it works

*With sufficient input material

clonoSEQ is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.

 

Resources

Samples collected will be sent to Adaptive Biotechnologies® for testing.  clonoSEQ will be performed, reported and billed by Adaptive Biotechnologies.  Labcorp insurance contracts do not apply.  Adaptive Biotechnologies and Labcorp are independent providers.  For more information, visit www.clonoseq.com.